Casma Therapeutics Announces CEO Transition Portfolio News / Karina Tin January 31, 2023 Casma Therapeutics Announces CEO Transition Read More »
Ribon Therapeutics Announces $25 Million Equity Investment from Pfizer Portfolio News / Karina Tin January 30, 2023 Ribon Therapeutics Announces $25 Million Equity Investment from Pfizer Read More »
Escient Pharmaceuticals Announces IND Clearance by FDA To Start Phase 1 Study of EP262, A First-in-Class Oral MRGPRX2 Antagonist For Mast Cell Mediated Disorders Portfolio News / Karina Tin January 30, 2023 Escient Pharmaceuticals Announces IND Clearance by FDA To Start Phase 1 Study of EP262, A First-in-Class Oral MRGPRX2 Antagonist For Mast Cell Mediated Disorders Read More »
Atavistik Bio Announces Collaboration with Plex Research to Enrich the Informatics Capabilities of its AMPS Platform and Accelerate the Discovery of Novel Small Molecule Therapeutics Portfolio News / Karina Tin January 10, 2023 Atavistik Bio Announces Collaboration with Plex Research to Enrich the Informatics Capabilities of its AMPS Platform and Accelerate the Discovery of Novel Small Molecule Therapeutics Read More »
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones Portfolio News / Karina Tin January 9, 2023 ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones Read More »
NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities Portfolio News / Karina Tin January 9, 2023 NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities Read More »
Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones Portfolio News / Karina Tin January 9, 2023 Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones Read More »
Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities Portfolio News / Karina Tin January 9, 2023 Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities Read More »
Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics Portfolio News / Karina Tin January 6, 2023 Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics Read More »
Carmot Therapeutics Launches Spin-Off, Kimia Therapeutics, to Focus on Metabolic Disease Portfolio News / Karina Tin January 5, 2023 Carmot Therapeutics Launches Spin-Off, Kimia Therapeutics, to Focus on Metabolic Disease Read More »
